Drug Trial Radar · NCT00491829
Flibanserin Versus Placebo in Premenopausal Women With HSDD
Last checked: Nov 20, 2026Latest source record: Jun 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
945
Actual
Start
Jun 2007
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women. To evaluate safety and tolerability of flibanserin in such patients.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
50 mg qhsDrug
flibanserin 50 mg
100 mgDrug
flibanserin 100mg
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary.Time frame: baseline to 24 weeks
Locations
86 sites in 13 countries. Site status is shown where the registry gives one.
511.77.43005 Boehringer Ingelheim Investigational Site
Innsbruck, Austria
511.77.43001 Boehringer Ingelheim Investigational Site
Vienna, Austria
511.77.43002 Boehringer Ingelheim Investigational Site
Vienna, Austria
511.77.43004 Boehringer Ingelheim Investigational Site
Vienna, Austria
511.77.43006 Boehringer Ingelheim Investigational Site
Wörgl, Austria
511.77.32004 Boehringer Ingelheim Investigational Site
Braine-l'Alleud, Belgium
511.77.32003 Boehringer Ingelheim Investigational Site
Edegem, Belgium
511.77.32005 Boehringer Ingelheim Investigational Site
Ghent, Belgium
511.77.32006 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
511.77.32002 Boehringer Ingelheim Investigational Site
Yvoir, Belgium
511.77.42001 Boehringer Ingelheim Investigational Site
Olomouc, Czechia
511.77.42002 Boehringer Ingelheim Investigational Site
Prague, Czechia
511.77.42003 Boehringer Ingelheim Investigational Site
Prague, Czechia
511.77.42004 Boehringer Ingelheim Investigational Site
Vřesina, Czechia
511.77.35801 Boehringer Ingelheim Investigational Site
Espoo, Finland
511.77.35805 Boehringer Ingelheim Investigational Site
Helsinki, Finland
511.77.35802 Boehringer Ingelheim Investigational Site
Oulu, Finland
511.77.35803 Boehringer Ingelheim Investigational Site
Seinäjoki, Finland
511.77.35804 Boehringer Ingelheim Investigational Site
Tampere, Finland
511.77.3308A Boehringer Ingelheim Investigational Site
Blanquefort, France
511.77.3301A Boehringer Ingelheim Investigational Site
Bordeaux, France
511.77.3305A Boehringer Ingelheim Investigational Site
La Rochelle, France
511.77.3314A Boehringer Ingelheim Investigational Site
Lille, France
511.77.3314B Cabinet médical
Lille, France
511.77.3314C Cabinet médical
Lille, France
511.77.3303A Boehringer Ingelheim Investigational Site
Marseille, France
511.77.3310A Boehringer Ingelheim Investigational Site
Marseille, France
511.77.3312A Boehringer Ingelheim Investigational Site
Marseille, France
511.77.3302A Boehringer Ingelheim Investigational Site
Paris, France
511.77.3315A Cabinet Médical
Rennes, France
511.77.3306A Boehringer Ingelheim Investigational Site
Saint-Émilion, France
511.77.3311A Boehringer Ingelheim Investigational Site
Toulouse, France
511.77.49004 Boehringer Ingelheim Investigational Site
Berlin, Germany
511.77.49007 Boehringer Ingelheim Investigational Site
Bochum, Germany
511.77.49001 Boehringer Ingelheim Investigational Site
Bonn, Germany
511.77.49006 Boehringer Ingelheim Investigational Site
Dresden, Germany
511.77.49008 Boehringer Ingelheim Investigational Site
Frankfurt, Germany
511.77.49003 Boehringer Ingelheim Investigational Site
Freiburg im Breisgau, Germany
511.77.49002 Boehringer Ingelheim Investigational Site
Hanover, Germany
511.77.49005 Boehringer Ingelheim Investigational Site
Leipzig, Germany
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.